About to BOOMcompany is about to publish thier clinical result of their ph3 trial in the next days
GoodLuck
enjoy the ride
technical above 8$ was good trigger
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.19USD
−29.07 MUSD
0.00USD
18.76 M
About Enlivex Therapeutics Ltd.
Sector
Industry
CEO
Oren Hershkovitz
Website
Headquarters
Ness Ziona
Founded
2012
ISIN
IL0011319527
FIGI
BBG005ZL1Z86
Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded by Dror Mevorach on January 22, 2012 and is headquartered in Ness Ziona, Israel.
ENLV Israel - Praying it doesnt break down this channelWith the evolution of covid variants, i believe this is one of the possible solution to serious covid reactions. It is competitors of course are vaccine makers.
Are we going to keep relying on vaccine makers. Or can we rely on something like what ENLV has?
Based on my research, ENLV is in the midst
Hope this 6.50 holds. The last time it was this low was long agoJust hold this doesn't break below this trendline. Otherwise, it will likely head to 5.
the RSI and MACD is already showing it is oversold.The last time it was 6.50 was awhile back.
$ENLV Target 17.10 for 31.34% $ENLV Target 17.10 for 31.34%
Or next add level is at 8.94
Anywhere around here is a good place to add...
—
On the far right of the chart is my Average (Grey) Current Target (Green), and Next Level to add (Red) Percentage to target is from my average.
I start every position with 1% of my acco
ADDED to $ENLV New Target 18.02 for 29.27% $ENLV Target 18.02 for 29.27%
Or next add level is at 9.86
—
On the far right of the chart is my Average (Grey) Current Target (Green), and Next Level to add (Red) Percentage to target is from my average.
I start every position with 1% of my account and build from there as needed and as possib
$ENLV Target 19.39 for 26.65% $ENLV Target 19.39 for 26.65%
Or next add level is at anywhere around here but I can’t add yet.
This one is actually really starting to look bullish... running out of steam on the down side... I am going to double my position here tomorrow, I think. There are a few other moves I'm thinking abou
ADDED to $ENLV New Target 20.08 for 25.50% ADDED to $ENLV Target 20.08 for 25.50%
Or next add level is at 11.92
I am not your financial advisor. Watch my setups first before you jump in… My trade set ups work very well and they are for my personal reference and if you decide to trade them you do so at your own risk. I will gladly answ
ENLV
Enlivex and Mount Sinai Health System Announce Research Collaboration for the Development of Allocetra in Combination with Immune Checkpoint Inhibitors.
In addition to the Sepsis for which it was developed, the drug Allocetra has other applications such as severe patients with Covid 19 '
auto
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of ENLV is 1.30 USD — it has increased by 0.74% in the past 24 hours. Watch Enlivex Therapeutics Ltd. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Enlivex Therapeutics Ltd. stocks are traded under the ticker ENLV.
ENLV stock has fallen by −12.26% compared to the previous week, the month change is a −14.47% fall, over the last year Enlivex Therapeutics Ltd. has showed a −19.25% decrease.
We've gathered analysts' opinions on Enlivex Therapeutics Ltd. future price: according to them, ENLV price has a max estimate of 13.00 USD and a min estimate of 6.00 USD. Watch ENLV chart and read a more detailed Enlivex Therapeutics Ltd. stock forecast: see what analysts think of Enlivex Therapeutics Ltd. and suggest that you do with its stocks.
ENLV reached its all-time high on Jul 31, 2014 with the price of 264.00 USD, and its all-time low was 1.15 USD and was reached on Apr 15, 2024. View more price dynamics on ENLV chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ENLV stock is 17.12% volatile and has beta coefficient of 1.96. Track Enlivex Therapeutics Ltd. stock price on the chart and check out the list of the most volatile stocks — is Enlivex Therapeutics Ltd. there?
Today Enlivex Therapeutics Ltd. has the market capitalization of 29.11 M, it has decreased by −9.21% over the last week.
Yes, you can track Enlivex Therapeutics Ltd. financials in yearly and quarterly reports right on TradingView.
Enlivex Therapeutics Ltd. is going to release the next earnings report on Dec 2, 2024. Keep track of upcoming events with our Earnings Calendar.
ENLV earnings for the last quarter are −0.12 USD per share, whereas the estimation was −0.22 USD resulting in a 45.45% surprise. The estimated earnings for the next quarter are −0.18 USD per share. See more details about Enlivex Therapeutics Ltd. earnings.
ENLV net income for the last quarter is −3.10 M USD, while the quarter before that showed −4.14 M USD of net income which accounts for 25.22% change. Track more Enlivex Therapeutics Ltd. financial stats to get the full picture.
No, ENLV doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 5, 2024, the company has 49.00 employees. See our rating of the largest employees — is Enlivex Therapeutics Ltd. on this list?
Like other stocks, ENLV shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Enlivex Therapeutics Ltd. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Enlivex Therapeutics Ltd. technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Enlivex Therapeutics Ltd. stock shows the sell signal. See more of Enlivex Therapeutics Ltd. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.